Abstract
In vivo, inhibition of fetal hemoglobin (HbF) expression in humans around the time of birth causes the clinical manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model was utilized to further explore the inhibition of HbF by adenosine derivative molecules. SQ22536 demonstrated down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy adenosine and 2′,3′-dideoxy adenosine had effects on HbF comparable to SQ22536. Other adenosine derivative molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF in matched cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.
Original language | English (US) |
---|---|
Pages (from-to) | 504-510 |
Number of pages | 7 |
Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Volume | 1782 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2008 |
Keywords
- Adenosine derivative
- Cytokine
- HbF inhibition
- Hemoglobinopathy
- Human erythropoiesis
- SQ22536
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology